{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:51:45Z","timestamp":1770328305772,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T00:00:00Z","timestamp":1243382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00520-009-0655-x","type":"journal-article","created":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T20:11:29Z","timestamp":1243282289000},"page":"321-328","source":"Crossref","is-referenced-by-count":17,"title":["Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8"],"prefix":"10.1007","volume":"18","author":[{"given":"Ann E.","family":"Kearns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald W.","family":"Northfelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela J.","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Kendrith M.","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyotsna","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todor","family":"Dentchev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,27]]},"reference":[{"key":"655_CR1","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1210\/jc.86.6.2787","volume":"86","author":"SA Stoch","year":"2001","unstructured":"Stoch SA, Parker RA, Chen L et al (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787\u20132791. doi:\n                    10.1210\/jc.86.6.2787","journal-title":"J Clin Endocrinol Metab"},{"key":"655_CR2","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM et al (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410\u20136417. doi:\n                    10.1210\/jc.2005-0183","journal-title":"J Clin Endocrinol Metab"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL et al (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164. doi:\n                    10.1056\/NEJMoa041943","journal-title":"N Engl J Med"},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897\u20137903. doi:\n                    10.1200\/JCO.2004.00.6908","journal-title":"J Clin Oncol"},{"key":"655_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","volume":"331","author":"EP Smith","year":"1994","unstructured":"Smith EP, Boyd J, Frank GR et al (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056\u20131061. doi:\n                    10.1056\/NEJM199410203311604","journal-title":"N Engl J Med"},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1210\/jc.80.12.3689","volume":"80","author":"A Morishima","year":"1995","unstructured":"Morishima A, Grumbach MM, Simpson ER et al (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689\u20133698. doi:\n                    10.1210\/jc.80.12.3689","journal-title":"J Clin Endocrinol Metab"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1210\/jc.2003-030736","volume":"88","author":"L Gennari","year":"2003","unstructured":"Gennari L, Merlotti D, Martini G et al (2003) Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 88:5327\u20135333. doi:\n                    10.1210\/jc.2003-030736","journal-title":"J Clin Endocrinol Metab"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1210\/jc.86.8.3555","volume":"86","author":"S Khosla","year":"2001","unstructured":"Khosla S, Melton LJ 3rd, Atkinson EJ et al (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555\u20133561. doi:\n                    10.1210\/jc.86.8.3555","journal-title":"J Clin Endocrinol Metab"},{"key":"655_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1210\/jc.86.1.192","volume":"86","author":"P Szulc","year":"2001","unstructured":"Szulc P, Munoz F, Claustrat B et al (2001) Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 86:192\u2013199. doi:\n                    10.1210\/jc.86.1.192","journal-title":"J Clin Endocrinol Metab"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archinternmed.2007.2","volume":"168","author":"C Meier","year":"2008","unstructured":"Meier C, Nguyen TV, Handelsman DJ et al (2008) Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168:47\u201354. doi:\n                    10.1001\/archinternmed.2007.2","journal-title":"Arch Intern Med"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1359\/jbmr.080518","volume":"23","author":"D Mellstrom","year":"2008","unstructured":"Mellstrom D, Vandenput L, Mallmin H et al (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23:1552\u20131560. doi:\n                    10.1359\/jbmr.080518","journal-title":"J Bone Miner Res"},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1172\/JCI10942","volume":"106","author":"A Falahati-Nini","year":"2000","unstructured":"Falahati-Nini A, Riggs BL, Atkinson EJ et al (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553\u20131560. doi:\n                    10.1172\/JCI10942","journal-title":"J Clin Invest"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038\u20131042. doi:\n                    10.1200\/JCO.2006.07.3361","journal-title":"J Clin Oncol"},{"key":"655_CR14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948\u2013955. doi:\n                    10.1056\/NEJMoa010845","journal-title":"N Engl J Med"},{"key":"655_CR15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL et al (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146:416\u2013424","journal-title":"Ann Intern Med"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","volume":"179","author":"MR Smith","year":"2008","unstructured":"Smith MR, Malkowicz SB, Chu F et al (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179:152\u2013155. doi:\n                    10.1016\/j.juro.2007.08.137","journal-title":"J Urol"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"MR Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H et al (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841\u20133846. doi:\n                    10.1210\/jc.2003-032058","journal-title":"J Clin Endocrinol Metab"},{"key":"655_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","volume":"31","author":"SJ Pocock","year":"1975","unstructured":"Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31:103\u2013115. doi:\n                    10.2307\/2529712","journal-title":"Biometrics"},{"key":"655_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2307\/2532573","volume":"49","author":"JF Hilton","year":"1993","unstructured":"Hilton JF, Mehta CR (1993) Power and sample size calculations for exact conditional tests with ordered categorical data. Biometrics 49:609\u2013616. doi:\n                    10.2307\/2532573","journal-title":"Biometrics"},{"key":"655_CR20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","volume":"52","author":"SS Shapiro","year":"1965","unstructured":"Shapiro SS, Wilk MB (1965) An analysis of variance test for normality. Biometrika 52:591\u2013611","journal-title":"Biometrika"},{"key":"655_CR21","first-page":"127","volume":"57","author":"BJ Kiralti","year":"2001","unstructured":"Kiralti BJ (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57:127\u2013132","journal-title":"Urology"},{"key":"655_CR22","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","volume":"289","author":"RT Chlebowski","year":"2003","unstructured":"Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243\u20133253. doi:\n                    10.1001\/jama.289.24.3243","journal-title":"JAMA"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0655-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0655-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:30:33Z","timestamp":1581960633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0655-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,27]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0655-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,27]]}}}